Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18

HOS-112098 · Präparat HOS-093615

Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Edoxaban Potential for increased edoxaban Exercise caution when edoxaban is concentrations which can result in a higher used with REYATAZ. risk of bleeding. The mechanism of interaction is P-gp inhibition by Please refer to the edoxaban SmPC REYATAZ/ritonavir. sections 4.2 and 4.5 for appropriate edoxaban dosage recommendations Ritonavir is a strong P-gp inhibitor. for co-administration with P-gp inhibitors. Potential P-gp inhibition by REYATAZ is unknown and cannot be excluded. Vitamin K antagonists Warfarin Co-administration with REYATAZ has the It is recommended that the potential to increase or decrease warfarin International Normalised Ratio concentrations. (INR) be monitored carefully during treatment with REYATAZ, especially when commencing therapy. ANTIEPILEPTICS Carbamazepine REYATAZ may increase plasma levels of Carbamazepine in combination carbamazepine due to CYP3A4 inhibition. with REYATAZ (with or without ritonavir) is contraindicated due to Due to carbamazepine inducing effect, a the risk for loss of virologic reduction in REYATAZ exposure cannot response and development of be ruled out. resistance (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) vitamin K (HOS-091176) edoxaban (HOS-086234) ritonavir (HOS-084521) warfarin (HOS-085950)